Working… Menu

CANVAS - CANagliflozin cardioVascular Assessment Study (CANVAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01032629
Recruitment Status : Completed
First Posted : December 15, 2009
Results First Posted : December 7, 2018
Last Update Posted : December 7, 2018
The George Institute for Global Health, Australia
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Brief Summary:

The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE). Other objectives include evaluating the overall safety, tolerability, and effectiveness of canagliflozin.

The data from this study will be combined with the data from CANVAS-R study (Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects with T2DM, NCT01989754) in a pre-specified integrated analysis of CV safety outcomes to satisfy US FDA post-marketing requirements for canagliflozin.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Cardiovascular Diseases Risk Factors Drug: Placebo Drug: Canagliflozin (JNJ-28431754) 100 mg Drug: Canagliflozin (JNJ-28431754) 300 mg Phase 3

Detailed Description:
The study will evaluate canagliflozin compared to placebo on CV events including CV death, heart attack, and stroke in patients with T2DM, whose diabetes is not well controlled at the beginning of the study and who have a history of CV events or have a high risk for CV events. The study includes 3 substudies which will compare the effectiveness of lowering blood glucose and assess the safety of canagliflozin relative to placebo in patients receiving specific commonly-used diabetes agents. 4,330 participants will be randomly assigned to treatment with 1 of 2 doses of canagliflozin (100 or 300 mg) or placebo, in a 1:1:1 ratio. This study was originally designed to last for up to 9 years. As per FDA post-marketing requirements for canagliflozin, the study's last subject last visit will now occur when enough MACE events (ie, CV death, nonfatal myocardial infarction, nonfatal stroke) are accumulated between the CANVAS (this study) and CANVAS-R studies. The completion target was reached in February 2017.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4330 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
Actual Study Start Date : December 9, 2009
Actual Primary Completion Date : February 22, 2017
Actual Study Completion Date : February 22, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo
Each patient will receive placebo (inactive medication) on background standard of care for diabetes once daily for the duration of the study
Drug: Placebo
One placebo capsule taken orally (by mouth) once daily

Experimental: Canagliflozin (JNJ-28431754) 100 mg
Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily on background standard of care for diabetes once daily for the duration of the study
Drug: Canagliflozin (JNJ-28431754) 100 mg
One 100 mg capsule taken orally (by mouth) once daily

Experimental: Canagliflozin (JNJ-28431754) 300 mg
Each patient will receive canagliflozin (JNJ-28431754) 300 mg once daily on background standard of care for diabetes once daily for the duration of the study
Drug: Canagliflozin (JNJ-28431754) 300 mg
One 300 mg capsule taken orally (by mouth) once daily

Primary Outcome Measures :
  1. Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke [ Time Frame: Up to approximately 8 years ]
    MACE, defined as a composite of CV death, non-fatal MI, and nonfatal stroke. Adjudication of these events by the Endpoint Adjudication Committee (EAC) was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of MACE are presented.

Secondary Outcome Measures :
  1. Change From Baseline in Homeostasis Model Assessment 2 Steady-State Beta-Cell Function (HOMA2-%B) at the End-of-Treatment (EOT) [ Time Frame: Baseline and end of treatment (approximately 338 weeks) ]
    The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100 percent.

  2. Percentage of Participants With Progression of Albuminuria at the End-of-Treatment [ Time Frame: End of treatment (approximately 338 weeks) ]
    Progression defined as the development of micro-albuminuria (albumin/creatinine ratio (ACR) greater than or equal to [>=] 30 milligram per gram (mg/g) and less than or equal to <= 300 mg/g) or macroalbuminuria (ACR of >300 mg/g) in a participant with baseline normoalbuminuria or the development of macro-albuminuria in a participant with baseline microalbuminuria. Percentage of participants with progression of albuminuria at the end-of-treatment were assessed.

  3. Change From Baseline in Proinsulin/Insulin (PI/I) Ratio at the End-of-Treatment [ Time Frame: Baseline and end of treatment (approximately 338 weeks) ]
    A raised proinsulin-to-insulin ratio due to impaired processing of proinsulin is an early marker of beta cell dysfunction. Beta-cell dysfunction was evaluated by calculating the PI/I ratio, which estimates the capacity of beta cells to convert proinsulin to insulin and may represent an acceptable method to indicate the degree of beta-cell secretion.

  4. Change From Baseline in Urinary Albumin/Creatinine Ratio at End-of-Treatment [ Time Frame: Baseline and End of treatment (approximately 338 weeks) ]
    Urinary Albumin/Creatinine Ratio is a potential marker of chronic kidney disease, calculated as a ratio of Urinary Albumin and Urinary Creatinine.

  5. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at End-of-Treatment [ Time Frame: Baseline and end of treatment (approximately 338 weeks) ]
    Change from baseline in Estimated Glomerular Filtration Rate (eGFR) was assessed at end of treatment. GFR is a measure of the rate at which blood is filtered by the kidney. Modification of Diet in Renal Disease (MDRD) is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and sex. eGFR milliliters/minute/1.73 meters square (mL/min/1.73 m^2) = 175 * (serum creatinine) ^ 1.154 * (Age) ^-0.203 *(0.742 if female) * (1.21 if Black).

  6. Change From Baseline in Glycated Hemoglobin (HbA1c) at End-of-Treatment [ Time Frame: Baseline and end of treatment (approximately 338 weeks) ]
    Change from baseline in glycated hemoglobin (HbA1c) percentage (%) was assessed at end of treatment. Glycated hemoglobin is a form of hemoglobin that is measured primarily to identify the average glucose concentration in the blood.

  7. Change From Baseline in Fasting Plasma Glucose (FPG) Levels at End-of-Treatment [ Time Frame: Baseline and end of treatment (approximately 338 weeks) ]
    Change from baseline in the fasting plasma glucose levels at end-of-treatment was assessed.

  8. Percent Change From Baseline in Body Weight at End-of-Treatment [ Time Frame: Baseline and end of treatment (approximately 338 weeks) ]
    Percent change from baseline in body weight was assessed at the end of treatment.

  9. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End-of-Treatment [ Time Frame: Baseline and end of treatment (approximately 338 weeks) ]
    Change from baseline in systolic blood pressure and diastolic blood pressure was assessed.

  10. Change From Baseline in Triglycerides Levels at End-of-Treatment [ Time Frame: Baseline and end of treatment (approximately 338 weeks) ]
    Change from baseline in triglycerides levels was assessed.

  11. Change From Baseline in Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) Levels at End-of-Treatment [ Time Frame: Baseline and end of treatment (approximately 338 weeks) ]
    Change from baseline in cholesterol, high-density lipoprotein cholesterol and low density lipoprotein cholesterol levels were assessed.

  12. Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) to High-Density Lipoprotein-Cholesterol (HDL-C) Ratio at End-of-Treatment [ Time Frame: Baseline and end of treatment (approximately 338 weeks) ]
    Change from baseline in LDL-C to HDL-C ratio was assessed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have a diagnosis of type 2 diabetes mellitus and greater than or equal to (>=) 30 yrs old with history of cardiovascular (CV) event, or >= 50 yrs old with high risk of CV events
  • Patients must have inadequate diabetes control (as defined by glycosylated hemoglobin greater than or equal to 7.0% to less than or equal to 10.5% at screening) and be either (1) not currently on diabetes drug therapy or (2) on therapy with any approved class of diabetes drugs

Exclusion Criteria:

  • A history of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
  • History of one or more severe hypoglycemic (ie, very low blood sugar) episode within 6 months before screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01032629

  Hide Study Locations
Layout table for location information
United States, Alabama
Birmingham, Alabama, United States
United States, Arizona
Mesa, Arizona, United States
Tucson, Arizona, United States
United States, California
La Mesa, California, United States
Los Gatos, California, United States
Pismo Beach, California, United States
Stockton, California, United States
Walnut Creek, California, United States
United States, Florida
Doral, Florida, United States
Fort Lauderdale, Florida, United States
Jacksonville, Florida, United States
Miami, Florida, United States
Plantation, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Duluth, Georgia, United States
United States, Idaho
Boise, Idaho, United States
Eagle, Idaho, United States
Meridian, Idaho, United States
United States, Illinois
Peoria, Illinois, United States
United States, Kansas
Topeka, Kansas, United States
United States, Kentucky
Crestview Hills, Kentucky, United States
Lexington, Kentucky, United States
United States, Maine
Auburn, Maine, United States
Scarborough, Maine, United States
United States, Maryland
Oxon Hill, Maryland, United States
United States, Michigan
Royal Oak, Michigan, United States
United States, Missouri
Kansas City, Missouri, United States
Saint Louis, Missouri, United States
United States, Nebraska
Omaha, Nebraska, United States
United States, New Jersey
Camden, New Jersey, United States
United States, New York
Bronx, New York, United States
Flushing, New York, United States
United States, North Carolina
Chapel Hill, North Carolina, United States
Charlotte, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Gallipolis, Ohio, United States
Mentor, Ohio, United States
Toledo, Ohio, United States
United States, Pennsylvania
Beaver, Pennsylvania, United States
Norristown, Pennsylvania, United States
Sayre, Pennsylvania, United States
United States, South Carolina
Greenville, South Carolina, United States
United States, Tennessee
Kingsport, Tennessee, United States
United States, Texas
Dallas, Texas, United States
Houston, Texas, United States
Odessa, Texas, United States
San Antonio, Texas, United States
Temple, Texas, United States
United States, Utah
Draper, Utah, United States
Salt Lake City, Utah, United States
Sandy, Utah, United States
West Jordan, Utah, United States
United States, Virginia
Danville, Virginia, United States
Richmond, Virginia, United States
United States, Washington
Spokane, Washington, United States
Tacoma, Washington, United States
Buenos Aires, Argentina
Capital Federal, Argentina
Ciudad Autonma Buenos Aires, Argentina
Ciudad Autonoma De Buenos Aires, Argentina
Cordoba, Argentina
Corrientes, Argentina
Godoy Cruz, Argentina
Mar Del Plata, Argentina
Rosario, Argentina
Santa Fe, Argentina
Auchenflower, Australia
Box Hill, Australia
Caboolture, Australia
Caringbah, Australia
Clayton, Australia
Daw Park, Australia
East Ringwood, Australia
Elizabeth Vale, Australia
Hornsby, Nsw 2077, Australia
Kippa Ring, Australia
Launceston, Australia
Liverpool, Australia
Melbourne, Australia
Milton, Australia
Parkville, Australia
Reservoir, Australia
Sherwood, Australia
Southport, Australia
St Leonards, Australia
West Heidelberg, Australia
Wollongong, Australia
Woolloongabba, Australia
Arlon, Belgium
Bonheiden, Belgium
Brussel, Belgium
Edegem, Belgium
Genk, Belgium
Leuven, Belgium
Canada, Alberta
Calgary, Alberta, Canada
Canada, British Columbia
Coquitlam, British Columbia, Canada
Canada, Manitoba
Winnipeg, Manitoba, Canada
Canada, Newfoundland and Labrador
St. John'S, Newfoundland and Labrador, Canada
Canada, Ontario
Brampton, Ontario, Canada
London, Ontario, Canada
Mississauga, Ontario, Canada
Nemarket, Ontario, Canada
Sarnia, Ontario, Canada
Sudbury, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Laval, Quebec, Canada
Lévis, Quebec, Canada
Montreal, Quebec, Canada
Val-Belair, Quebec, Canada
Canada, Saskatchewan
Saskatoon, Saskatchewan, Canada
Bogota, Colombia
Floridablanca, Colombia
Kralupy Nad Vltavou, Czechia
Moravsky Krumlov, Czechia
Olomouc 9, Czechia
Ostrava, Czechia
Pisek, Czechia
Prague 5, Czechia
Praha 11, Czechia
Praha 8, Czechia
Praha, Czechia
Znojmo N/A, Czechia
Pärnu, Estonia
Tallinn, Estonia
Tartu, Estonia
Viljandi, Estonia
Amiens, France
Nimes Cedex 9, France
Pessac, France
Berlin, Germany
Dortmund, Germany
Dresden, Germany
Hamburg, Germany
Künzing, Germany
Mainz, Germany
Münster, Germany
Pirna, Germany
Saarlouis, Germany
Speyer, Germany
Villingen-Schwenningen, Germany
Budapest, Hungary
Kecskemet, Hungary
Mosonmagyaróvár, Hungary
Zalaegerszeg, Hungary
Ahemadabad, India
Ahmedabad, India
Ambawadi, India
Bangalore, Karnataka, India
Bangalore, India
Belgaum, India
Calicut, India
Chennai, India
Cochin, India
Coimbatore, India
Ernakulam, India
Ghaziabad, India
Hyderabad, India
Indore, India
Jaipur, India
Karnal, India
Kerala, India
Kochi, India
Kolkata, India
Lucknow, India
Mangalore, India
Mumbai, India
Mysore, India
Nagpur, India
New Delhi, India
Patna, India
Pune, India
Rajkot, India
Trivandrum, Kerala, India
Vadodhara, India
Vijayawada, India
Visakhapatnam, India
Beer Sheba, Israel
Holon, Israel
Jerusalem, Israel
Kfar Saba, Israel
Luxembourg, Luxembourg
Georgetown, Malaysia
Johor Bahru, Malaysia
Kota Bharu, Malaysia
Kuala Lumpur N/A, Malaysia
Petaling Jaya, Malaysia
Pulau Pinang, Malaysia
Subang Jaya, Malaysia
Aguascalientes, Mexico
Celaya, Mexico
Ciudad De Mexico, Mexico
Durango, Mexico
Guadalajara, Mexico
Monterrey, Mexico
Almelo, Netherlands
Almere, Netherlands
Amsterdam, Netherlands
Arnhem, Netherlands
Delft, Netherlands
Den Helder, Netherlands
Dordrecht, Netherlands
Eindhoven, Netherlands
Groningen, Netherlands
Hoorn Nh, Netherlands
Rotterdam, Netherlands
Tilburg, Netherlands
Utrecht, Netherlands
Velp Gld, Netherlands
Zoetermeer, Netherlands
Zwijndrecht, Netherlands
New Zealand
Auckland, New Zealand
Christchurch, New Zealand
Dunedin, New Zealand
Tauranga, New Zealand
Wellington, New Zealand
Alesund, Norway
Asker, Norway
Bekkestua, Norway
Elverum, Norway
Hamar, Norway
Lierskogen, Norway
Moss, Norway
Oslo, Norway
Skedsmokorset, Norway
Bialystok, Poland
Ciechocinek, Poland
Gniewkowo, Poland
Grudziadz, Poland
Katowice, Poland
Krakow, Poland
Lublin, Poland
Plock, Poland
Poznan, Poland
Rzeszow, Poland
Slawkow, Poland
Torun, Poland
Warszawa, Poland
Wroclaw, Poland
Russian Federation
Arkhangelsk, Russian Federation
Chelyabinsk, Russian Federation
Ekaterinburg, Russian Federation
Kemerovo, Russian Federation
Kirov, Russian Federation
Kursk, Russian Federation
Moscow N/A, Russian Federation
Moscow, Russian Federation
Nizhny Novgorod, Russian Federation
Novosibirsk, Russian Federation
Omsk, Russian Federation
Penza, Russian Federation
Rostov-On-Don, Russian Federation
Russia, Russian Federation
Ryazan, Russian Federation
Saint Petersburg, Russian Federation
Saint-Petersburg, Russian Federation
Saratov, Russian Federation
Smolensk, Russian Federation
St Petersburg, Russian Federation
Tomsk, Russian Federation
Tula, Russian Federation
Tyumen, Russian Federation
Yaroslavl Nap, Russian Federation
Yaroslavl, Russian Federation
Alicante, Spain
Almeria, Spain
Barcelona, Spain
Figueres, Spain
Madrid, Spain
Málaga, Spain
Oviedo, Spain
Reus, Spain
Sabadell, Spain
San Juan De Alicante, Spain
Santiago De Compostela, Spain
Sevilla N/A, Spain
Valencia, Spain
Viladecans, Spain
Borås, Sweden
Göteborg, Sweden
Helsingborg, Sweden
Lund, Sweden
Malmö, Sweden
Oskarshamn N/A, Sweden
Piteå, Sweden
Stockholm, Sweden
Uddevalla, Sweden
Dnepropetrovsk, Ukraine
Donetsk, Ukraine
Kharkov, Ukraine
Kiev, Ukraine
Kyiv, Ukraine
Odessa, Ukraine
Ternopol, Ukraine
Uzhgorod, Ukraine
Vinnitsa, Ukraine
Zaporozhye, Ukraine
United Kingdom
Belfast, United Kingdom
Blackburn, United Kingdom
Bolton, United Kingdom
Chorley, United Kingdom
Derby, United Kingdom
Glasgow, United Kingdom
Hull, United Kingdom
Leicester, United Kingdom
Liverpool, United Kingdom
Londonderry, United Kingdom
London, United Kingdom
Manchester, United Kingdom
Randalstown, United Kingdom
Salford, United Kingdom
York, United Kingdom
Sponsors and Collaborators
Janssen Research & Development, LLC
The George Institute for Global Health, Australia
Layout table for investigator information
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
  Study Documents (Full-Text)

Documents provided by Janssen Research & Development, LLC:
Study Protocol  [PDF] May 5, 2016
Statistical Analysis Plan  [PDF] March 20, 2017

Publications automatically indexed to this study by Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Janssen Research & Development, LLC Identifier: NCT01032629     History of Changes
Other Study ID Numbers: CR016627
28431754DIA3008 ( Other Identifier: Janssen Research & Development, LLC )
2009-012140-16 ( EudraCT Number )
First Posted: December 15, 2009    Key Record Dates
Results First Posted: December 7, 2018
Last Update Posted: December 7, 2018
Last Verified: November 2018

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Janssen Research & Development, LLC:
Type 2 diabetes mellitus
Cardiovascular risk
Cardiovascular outcomes
Canagliflozin (JNJ-28431754)
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Cardiovascular Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Sodium-Glucose Transporter 2 Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs